Recent developments
Regulatory expansions
CDMOs expanded regulatory coverage. AGC Biologics secured Anvisa GMP certification for the Seattle site, opening Brazil supply. WuXi Biologics obtained MHRA GMP certification for DP5 and DPPC for an ophthalmic biologic and added GMP certification from Türkiye’s TITCK across three Wuxi facilities.
Footprint and capacity
Network shifts continued. Terumo completed the acquisition of the Leverkusen drug product plant from WuXi Biologics, adding EU fill‑finish capacity. WuXi outlined regional growth via an MoU with the Qatar Free Zones Authority. Merck advanced U.S. manufacturing through a new $3B Elkton facility.
Advanced therapies services
CDMOs deepened roles in cell and gene modalities. AGC supported marketing authorization for Waskyra gene therapy. BBG and SEQENS formed a transatlantic ATMP manufacturing partnership. WuXi expanded services via a license and research service agreement with Vertex, a partnership to develop SND006, and a strategic collaboration with HanchorBio.
Technology and inputs
Process intensification and enabling materials advanced. WuXi launched the PatroLab digital twin platform for real‑time monitoring and predictive control. Toray introduced a high-efficiency separation membrane module to mitigate purification bottlenecks. Evonik added EUDRACAP colon functional capsules and MaxiPure Polysorbate 80; plus Noblyst F catalysts for flow applications.
Supply and sustainability
Input security and ESG progressed. Brenntag and Seqens agreed a sole distribution partnership with Seqens for non‑GMP intermediates in Europe. Croda and Amino launched BioXPro high‑purity amino acids. WuXi reported inclusion in the S&P Global Sustainability Yearbook 2026 and an EcoVadis Platinum Medal, and achieved ISO 20400 certification for sustainable procurement and CDP “A” ratings for climate and water.